Clinical Report: Roswell Park Offering CAR T Trial for Autoimmune Conditions

Overview

A new phase 1 trial at Roswell Park Comprehensive Cancer Center is exploring CAR T-cell therapy for patients with autoimmune conditions such as systemic lupus, lupus nephritis, and systemic sclerosis. This trial aims to achieve a deep immune reset and improve long-term control of these refractory conditions.

Background

CAR T-cell therapies have predominantly been used in oncology, but there is growing interest in their application for autoimmune diseases. The unique properties of gamma-delta T-cells in this trial may offer advantages in targeting inflamed tissues while minimizing inflammatory responses. Understanding the potential of CAR T-cell therapy in autoimmune conditions could lead to transformative treatment options for patients who have not responded to conventional therapies.

Data Highlights

No numerical data available in the source material.

Key Findings

• The trial is led by Dr. Alicia Lieberman at Roswell Park Comprehensive Cancer Center.
• Patients with systemic lupus, lupus nephritis, or systemic sclerosis are being recruited for the trial.
• The therapy involves chemotherapy followed by infusion of CD20-directed CAR T-cells.
• This is the only trial in the U.S. utilizing this specific CAR T-cell product.
• Gamma-delta T-cells are noted for their ability to home to inflamed tissues and secrete fewer inflammatory cytokines.

Clinical Implications

The ongoing trial may provide insights into the efficacy of CAR T-cell therapy for autoimmune conditions, potentially leading to new treatment paradigms. Clinicians should remain informed about the outcomes of this trial as it may influence future guidelines and treatment strategies for refractory autoimmune diseases.

Conclusion

The exploration of CAR T-cell therapy for autoimmune conditions at Roswell Park represents a significant step towards innovative treatment options. Continued research in this area is essential to determine the safety and efficacy of such therapies in non-oncological settings.

References

1. Roswell Park Comprehensive Cancer Center, Source, 2023 -- New CAR T-Cell Therapy Shows Promise as ‘Magic Bullet’ for Patients with Relapsed/Refractory AML — Even After Transplant
2. Roswell Park Comprehensive Cancer Center, Source, 2023 -- Clinical Trial Offers CAR T-Cell Therapy Targeting MUC16 for Recurrent/Refractory Ovarian Cancer
3. UCI Health, Source, 2023 -- Clinical trial tests promising CAR T-cell therapy for lupus
4. Roswell Park Comprehensive Cancer Center, Source, 2023 -- Join Roswell Park Revolutionaries for Cell Therapy Symposium at ASH
5. Rheumatology.org, Source, 2023 -- Guidelines on CAR T-cell therapy for autoimmune diseases
6. NEJM, Source, 2024 -- Evidence on CAR T-cell therapy for autoimmune diseases
7. Roswell Park Comprehensive Cancer Center, Source, 2023 -- Roswell Park Offering CAR T Trial for Autoimmune Conditions
8. https://rheumatology.org/api/asset/bltec93920aad624e33
9. https://svenskreumatologi.se/wp-content/uploads/2026/01/muller-2024-nejm.pdf
10. Roswell Park Offering CAR T Trial for Autoimmune Conditions - Roswell Park Comprehensive Cancer Center